Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Queissner, R; Lenger, M; Birner, A; Dalkner, N; Fellendorf, F; Bengesser, S; Platzer, M; Hamm, C; Maget, A; Reininghaus, B; Ratzenhofer, M; Schuller, J; Mangge, H; Kapfhammer, HP; Reininghaus, EZ.
The association between anti-inflammatory effects of long-term lithium treatment and illness course in Bipolar Disorder.
J Affect Disord. 2021; 281:228-234
Doi: 10.1016/j.jad.2020.11.063
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Birner Armin
- Queissner Robert
- Co-Autor*innen der Med Uni Graz
- Bengesser Susanne
- Dalkner Nina
- Fellendorf Frederike
- Hamm Carlo
- Kapfhammer Hans-Peter
- Lenger Melanie
- Maget Alexander
- Mangge Harald
- Platzer Martina
- Ratzenhofer Michaela
- Reininghaus Bernd
- Reininghaus Eva
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- INTRODUCTION: Altered levels of acute-phase proteins are often described in different conditions in BD. Nevertheless, data on the association between lithium treatment and inflammatory markers in the long-term course of BD are still missing. The aim of the study was to examine the long-term course of BD concerning long-term lithium treatment, chronic inflammatory processes and symptom progression. Furthermore, the association between duration of lithium treatment and levels of hsCRP was explored. METHODS: 267 individuals (males= 139, females= 128) with BD were included. Duration of lithium treatment as well as symptom progression, defined as the increase in severity of symptoms, number of episodes a year and duration of episodes within a period of 1.5 years in the past and hsCRP were evaluated. RESULTS: Male individuals with symptom progression over time had significantly lower duration of lithium treatment compared to individuals without symptoms progression (U= 47.4, p=.037). There were significantly higher levels of hsCRP in male individuals with symptom progression compared to males without symptom progression (U= 47.5, p=.027). Further, there was a significant negative correlation between the duration of lithium treatment and hsCRP levels in the whole sample (r= -.276, p<.05). CONCLUSION: Our results show that an altered inflammatory state may be associated with a more severe illness course in BD. Further, a longer duration of lithium treatment may be associated with lower symptom progression. The shown association between hsCRP-levels and lithium treatment duration suggests a potential anti-inflammatory effect of lithium as a mediator of its significant positive outcome effect in BD.
- Find related publications in this database (using NLM MeSH Indexing)
- Anti-Inflammatory Agents - therapeutic use
- Biomarkers - administration & dosage
- Bipolar Disorder - drug therapy
- Female - administration & dosage
- Humans - administration & dosage
- Lithium - adverse effects
- Lithium Compounds - therapeutic use
- Male - administration & dosage
- Find related publications in this database (Keywords)
- Bipolar disorder
- Inflammation
- Lithium
- Illness progression
- C-reactive Protein
- Long-term effects